U.S. and Israel Trigger Middle East War, Disrupting Pharma Air Routes

The Middle East war triggered by U.S. and Israeli attacks on Iran two weeks ago has severely disrupted critical pharmaceutical supply routes to Gulf countries.

“President Trump called on countries to assist in reopening the Strait of Hormuz, while Starmer said the UK is working with allies to restore naviga”

AnewZ

This conflict has created significant risks for cancer drugs and other temperature-sensitive medicines that require refrigeration and precise cold-chain management.

AnewZ

Industry executives report that the conflict has knocked out key air transit hubs and closed shipping routes.

These disruptions are snarling the movement of goods from medicines to food and oil across the region.

The Gulf's heavy reliance on imports has made the region particularly vulnerable to supply chain disruptions.

Many medicines have short shelf lives and need strict cold-chain storage, complicating alternative transportation solutions.

While major shortages have not yet been widely observed, multiple executives warned that this situation could deteriorate significantly if the conflict persists.

Major airports in the Middle East including Dubai, Abu Dhabi, and Doha have been closed due to Iranian strikes in response to U.S. and Israeli attacks.

These closures have crippled critical cargo hubs that form vital links between Europe, Asia, and Africa.

Devdiscourse

Dubai and Doha in particular handle large volumes of temperature-controlled pharmaceutical shipments through carriers including Emirates and Etihad.

Logistics firms such as DHL also depend on these hubs for pharmaceutical transport.

The closure of the Strait of Hormuz by Iran has made sea routes impractical due to access restrictions and longer transit times.

Industry data shows that more than a fifth of global air cargo is exposed to this disruption.

This air cargo represents the primary route for critical and life-saving drugs and vaccines worldwide.

Cancer drugs and other medicines requiring strict temperature control are particularly vulnerable to the supply chain disruptions.

“Analysis-Middle East war disrupts pharma air routes, risks cancer drugs supply _Reuters_ Published Dec 31, 0000 07:00PM ET Updated Mar 16, 2026 10:48AM ET”

M

Executives have identified monoclonal antibodies and other specialized treatments as being at highest risk.

These medicines must be kept within narrow temperature ranges to remain safe and effective.

They rely on tightly managed 'cold-chain' transport systems designed to maintain precise refrigeration throughout their journey.

Prashant Yadav, senior fellow for global health at the Council on Foreign Relations, highlighted that typical stock levels for such medicines in the Gulf run around three months.

Some customers have warned suppliers they could run low within four to six weeks if conditions do not improve.

The consequences of delays in oncology drug delivery are severe, potentially forcing patients to restart treatment courses or witness disease progression.

Pharmaceutical companies and logistics providers are implementing emergency response measures to mitigate the supply chain disruptions.

Companies are rerouting shipments through alternative airports and establishing overland transportation routes.

Pharmaceutical Executive

Western drug companies are seeking alternative routes into the Gulf by trucking some drugs overland from airports like Jeddah and Riyadh in Saudi Arabia.

Other alternative routing options include Istanbul and Oman.

One medical device company executive described their approach as first mapping shipments already in transit or ready to depart.

They then decide which pallets need to be diverted and whether new shipments must be planned.

Europe-Asia cargo typically moving through Dubai or Doha airports is being redirected through China or Singapore.

Executives caution that alternative 'cold-chain corridors' cannot be set up overnight and are not always available.

Some companies have set up internal teams to prioritize patient-critical shipments, including cancer treatments.

While some logistics providers report that supplies are currently holding, industry executives warn that the situation requires constant management.

“War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of cancer treatments and other temperature-sensitive medicines as key air and sea transit hubs are knocked out of operation”

Pharmaceutical Executive

Airspace restrictions shift rapidly, and risks will rise significantly if the conflict persists.

Reuters

Dorothee Becher, head of air logistics for healthcare at Kuehne+Nagel, noted that carriers are successfully reaching Gulf markets through alternative routes.

Healthcare cargo is being prioritized in the current routing strategies.

The disruption extends beyond finished medicines to potential shortages of packaging components.

These components include vial stoppers and IV bag plastics, which are themselves shipped through the affected routes.

David Weeks, who covers supply chain for Moody's, explained that shortages sometimes involve packaging components rather than the medicines themselves.

The potential for extended supply chain disruptions could lead to Gulf and Asian inventories beginning to run down.

This could create a cascading effect impacting healthcare systems across multiple regions.